Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 1,990 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

DexCom Stock Performance

DXCM opened at $134.30 on Friday. The company has a market capitalization of $51.77 billion, a price-to-earnings ratio of 102.52, a price-to-earnings-growth ratio of 2.35 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The business has a 50 day moving average price of $129.35 and a two-hundred day moving average price of $116.41.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.34 earnings per share. Research analysts predict that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on DXCM shares. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James raised their price objective on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $141.40.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently added to or reduced their stakes in the company. Centaurus Financial Inc. lifted its position in DexCom by 5.5% in the first quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after purchasing an additional 64 shares during the period. Stableford Capital II LLC increased its holdings in shares of DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares in the last quarter. Fortis Capital Advisors LLC increased its holdings in shares of DexCom by 5.5% in the second quarter. Fortis Capital Advisors LLC now owns 1,744 shares of the medical device company’s stock valued at $224,000 after buying an additional 91 shares in the last quarter. D Orazio & Associates Inc. increased its holdings in shares of DexCom by 0.8% in the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after buying an additional 93 shares in the last quarter. Finally, Gulf International Bank UK Ltd increased its holdings in shares of DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after buying an additional 93 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.